TOPIC

Advances in Oncology - The Revolution of Antibody Drug Conjugates

MODERATORS

Hope Rugo, MD, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, Medical Director of Cancer Infusion Services, UCSF Helen DIller Family Comprehensive Cancer Center

Laura Crocitto, MD, Vice President and Chief Medical Officer for Cancer Services, Medical Director, UCSF Helen Diller Family Comprehensive Cancer Center

-------

PRESENTATIONS

"Antibody Drug Conjugates in Urothelial Carcinoma, Present and Future"

Vadim Koshkin, MD, Associate Professor of Clinical Medicine, Division of Hematology/Oncology, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center

After completing this course, attendees will have improved their skills and strategies for:

• Understanding the recent developments and updates in the dynamic treatment landscape of metastatic urothelial cancer.
• Understanding the role of antibody drug conjugates in the treatment of advanced urothelial cancer.
• Learning about novel targets for antibody drug conjugates and future directions for their development in the treatment of advanced urothelial cancer.

-------

"Antibody Drug Conjugates in Non-Small Cell Lung Cancer"

Matthew Gubens, MD, MS, FASCO, Professor of Thoracic Medical Oncology, UCSF Helen DIller Family Comprehensive Cancer Center

After completing this course, attendees will have improved their skills and strategies for:

•  Explaining indications for currently FDA-approved ADCs in NSCLC.
• Explaining toxicities of currently FDA-approved ADCs in NSCLC.
• Discussing clinical trial data regarding ADCs in NSCLC not yet approved by the FDA.

-------

"New Directions in the Treatment of Breast Cancer with ADCs"

Hope S. Rugo, MD, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, Medical Director of Cancer Infusion Services, UCSF Helen Diller Family Comprehensive Cancer Center

After completing this course, attendees will have improved their skills and strategies for:

• Understanding new ADCs and application to clinical practice.
• Understanding ADC key toxicities and toxicity management.
• Understanding ADC ongoing clinical trials and new directions.

-------

REGISTRATION

To secure your spot, please register in advance. 

• REGISTER WITH CME
• REGISTER WITHOUT CME